C-Ray Therapeutics
C-Ray Therapeutics is a global CRDMO dedicated to advancing the development and
manufacturing of innovative radiopharmaceuticals. We provide end-to-end solutions—
from process development, preclinical evaluation, and IND-enabling studies to clinical
supply and commercial-scale cGMP production—supported by a robust global logistics
network. Our 28,000 m² state-of-the-art R&D and manufacturing facilities are equipped
with the highest Class A Radiation Safety License, enabling large-scale production
of 30+ radioisotopes. Our integrated preclinical center supports both small and large
animal studies, including in vivo imaging, biodistribution, and dosimetry analysis. To
date, we have successfully executed over 60 CRDMO projects worldwide, including
preclinical and molecular imaging studies, CDMO collaborations, and multiple programs
advancing through IND, IIT, and clinical supply stages—one of which has progressed to
a Phase III clinical trial. A core strength of C-Ray is our stable, diversified radionuclide
supply chain. We play a leading role in securing access to critical isotopes, including
Ac-225, and have supported 16 Ac-225–labeled programs globally. By building an
open “production–academia–research–application” platform, C-Ray is accelerating the
clinical translation of integrated diagnostic and therapeutic solutions. Our vision is to
set the global benchmark for innovation, reliability, and industrial transformation in the
radiopharmaceutical field.
